Loading...
Loading...
ACETO Corporation
ACET, a global leader in the marketing, sale and distribution of
products for Human Health, Pharmaceutical Ingredients and Performance
Chemicals, today announced that Rising Pharmaceuticals Inc., its finished
dosage form generics subsidiary, has launched the generic version of the
75mg/*5mL strength of Clindamycin Palmitate Hydrochloride for Oral Solution,
USP (Pediatric), an FDA approved generic version of Pfizer Inc.'s Cleocin
Pediatric®. According to IMS Health data, U.S. market sales for Clindamycin
Palmitate Hydrochloride, which is an antibiotic that is used to treat serious
infections caused by bacteria, were approximately $59 million for the twelve
months ended June 30, 2012.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in